|
Developmental Study on Fatigue in Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Developmental Study on Fatigue in Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Developmental Study on Fatigue in Cancer Clinical research trials and Developmental Study on Fatigue in Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Developmental Study on Fatigue in Cancer. Developmental Study on Fatigue in Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Developmental Study on Fatigue in Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Developmental Study on Fatigue in Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Developmental Study on Fatigue in Cancer  Developmental Study on Fatigue in Cancer
Developmental Study on Fatigue in Cancer
For Condition: Neoplasms
Status: Recruiting
Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) ,
Synopsis: L-carnitine is a supplement (type of vitamin) that has been suggested to be decreased in patients with cancer. We will identify patients that have terminal cancer and fatigue. The purpose of this study is to determine if L-carnitine replacement improves fatigue in cancer patients with L-carnitine deficiency.
Details: Fatigue is the most frequently reported symptom in patients with cancer. The causes of fatigue are multifactorial and include the disease itself, antineoplastic therapies, anemia, depression, and malnutrition. Our preliminary data suggest that micronutrient deficiencies, specifically carnitine deficiency, may be an important factor in fatigue. Carnitine plays a major role in energy metabolism. Systemic depletion is characterized by weight loss, fatigue, muscle weakness, decreased tolerance to metabolic stress, and cardiomyopathy. We found deficiency of the micronutrient carnitine in 17/27 patients with cancer. Symptoms of fatigue and functional status improved significantly in those patients who received oral L-carnitine supplementation. In addition, we observed similar results in 6/10 patients with end stage AIDS presenting with carnitine deficiency. Objectives: a) To determine the effect of L-carnitine therapy on symptoms of fatigue in patients with terminal cancer and serum carnitine deficiency, and b) to determine the effect of L-carnitine therapy on performance status, cognitive function, mood, quality of life, and motor activity in these patients. Study Design: We propose to conduct a Phase Il developmental randomized double-blind placebo-controlled study to determine the effect of the micronutrient L-carnitine on fatigue and other outcomes in patients with terminal cancer. A sample of 130 patients with terminal cancer, fatigue and serum carnitine deficiency will be recruited into the intervention study. At the first visit, the patients will receive a baseline assessment of fatigue, performance status, cognitive function, mood, and quality of life and motor activity. a) During weeks 1-4, patients will be randomized to receive L-carnitine, 2 g/day, placebo. b) During weeks 5-8, all patients will receive L-carnitine at a dose of 2 g/day, for a period of 4 weeks. Measures will be repeated at 48 hs, 2 weeks, 4 weeks and 8 weeks. The primary endpoint will be change in fatigue at 4 weeks. Analysis will evaluate group differences in the primary endpoint and other outcomes. An interim analysis will be done once 15 patients have been observed in each group at 4 weeks. Paired and unpaired data analyses between groups will be conducted with the assistance of a statistician.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion: - Patients with diagnosis of cancer and estimated life expectancy of less than 6 months. - Patients who have undergone antineoplastic therapy which may worsen fatigue or promote carnitine deficiency will be eligible if completed the therapy more than 90 days prior to beginning the study. Exclusion: - Uncontrolled or severe cardiovascular, pulmonary, or renal disease. - Patients with encephalopathy or psychiatric disorder sufficiently severe to impair completion of the questionnaire. - Treatment or replacement therapy with any form of carnitine less than 12 months prior to enrollment. - Known sensitivity to carnitine. - History of seizures or stroke.
Total Enrollment: 140
Location and Contact Information:
Overall Study Official:
RicardoCruciani, Principal Investigator, Beth Israel Medical Center, Department of Pain Medicine and Palliative Care
Beth Israel Medical Center *Recruiting*
New York City, New York, 10003
United States
Recruiting
Additional Information:
Study ID Numbers: 1 R21 AT01025-01;
Study Start Date: January 2002
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034450
Other Neoplasms Studies:
1. Meaning-Centered Psychotherapy in Advanced Cancer
2. A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies
3. A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors
4. Endolymphatic Sac Tumors in a Population of Patients with von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients with Early Stage Endolymphatic Sac Tumors
5. A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
Related Studies:
Other Neoplasms Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Developmental Study on Fatigue in Cancer
|
|
|
|
|
|
|
|
